New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg;   - tablet - 100 mcg - active: desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg   excipient: lactose monohydrate magnesium stearate maize starch povidone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.2mg equivalent to desmopressin 0.178 mg;   - tablet - 200 mcg - active: desmopressin acetate trihydrate 0.2mg equivalent to desmopressin 0.178 mg   excipient: lactose monohydrate magnesium stearate maize starch povidone

Israel - engelsk - Ministry of Health

ferring pharmaceuticals ltd - desmopressin as acetate - tablets soluble - desmopressin as acetate 60 mcg - desmopressin - desmopressin - nocturnal enuresis.

Israel - engelsk - Ministry of Health

ferring pharmaceuticals ltd - desmopressin as acetate - tablets soluble - desmopressin as acetate 120 mcg - desmopressin - desmopressin - nocturnal enuresis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 60 microgram (equivalent: desmopressin acetate, qty 68 microgram) - wafer - excipient ingredients: mannitol; citric acid; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes o

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of s

Malta - engelsk - Medicines Authority

ferring ireland limited united drug house, magna drive magna business park, citywest road dublin 24 , ireland - desmopressin acetate - nasal spray - desmopressin acetate 10 µg - pituitary and hypothalamic hormones and analogues

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.2 mg (equivalent: desmopressin, qty 178 microgram) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; povidone; potato starch - minirin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

USA - engelsk - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - nocdurna is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. in the nocdurna clinical trials nocturnal polyuria was defined as night-time urine production exceeding one-third of the 24-hour urine production. before starting nocdurna: - evaluate the patient for possible causes for the nocturia, including excessive fluid intake prior to bedtime, and address other treatable causes of nocturia. - confirm the diagnosis of nocturnal polyuria with a 24-hour urine collection, if one has not been obtained previously. nocdurna is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: - hyponatremia or a history of hyponatremia [see warnings and precautions (5.1)] . - polydipsia - concomitant use with loop diuretics [see warnings and precautions (5.1)] - concomitant use with systemic or inhaled glucocorticoids [see warnings and precautions (5.2), drug interactions (7.1)] - renal impairment with estimate